COVID 19 and tuberculosis

Chopra, K.K.; Arora, Vijay K.; Singh, Shweta

doi:10.1016/j.ijtb.2020.06.001

Cited by 30 publications

(26 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…National strategic plan for tuberculosis:, 2025 ). In 2019; India confirmed 24 lakh TB cases and over 79,000 mortalities ( Chopra, 2020 ). Moreover, TB is the biggest killer in India compared to Covid-19 ( Chopra, 2020 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The possible impact of socioeconomic, income, and educational status on adverse effects of drug and their therapeutic episodes in patients targeted with a combination of tuberculosis interventions

Imam

Sharma

Al-Harbi

et al. 2021

Saudi Journal of Biological Sciences

View full text Add to dashboard Cite

Highlights Socio-economic status is very important in patient receiving DOT therapy. Income influences disease occurrence as well as adverse events. Occupation increases the risk of diseases and results increase risk of adverse events. Low income results mal nutrition and increased risk of drug intolerance or adverse events. DOTS is an effective treatment strategy for MTB patients.

show abstract

Section: Introductionmentioning

confidence: 99%

“…In 2019; India confirmed 24 lakh TB cases and over 79,000 mortalities ( Chopra, 2020 ). Moreover, TB is the biggest killer in India compared to Covid-19 ( Chopra, 2020 ). In addition, India has now made a promising commitment to expel TB from the country by 2025.…”

Section: Introductionmentioning

confidence: 99%

The possible impact of socioeconomic, income, and educational status on adverse effects of drug and their therapeutic episodes in patients targeted with a combination of tuberculosis interventions

Imam

Sharma

Al-Harbi

et al. 2021

Saudi Journal of Biological Sciences

View full text Add to dashboard Cite

show abstract

“…Mandatory face masks, with special regards to particular masks, which is present in many countries globally, as a tool of combating COVID-19, also reduces the transmission of TB. It is understandable that COVID-19 is priority number one, however, one must not forget the incidence and mortality that TB causes daily [14][15][16][17].…”

Section: Discusionmentioning

confidence: 99%

Unrecognized tuberculosis in a patient with COVID-19

et al. 2021

View full text Add to dashboard Cite

Introduction. COVID-19 is responsible for the current global pandemic. Globally, over 15 million people are currently infected, and just over 600,000 have died due to being infected. It is known that people with chronic illnesses and compromised immune systems can develop more severe clinical presentation. Tuberculosis is still one of the biggest epidemiological problems worldwide. Both of these diseases can be misdiagnosed and can manifest in a similar way. We will present a case study of a patient who was initially treated as a COVID-19 infection, with Tuberculosis being diagnosed later on. The recovery began only after being treated for both diseases simultaneously. Case report. The patient is a 27-year-old male, non-smoker, with no history of any significant diseases. He presented with fever, fatigue and hemoptysis. Computed tomography pulmoangiography had shown massive consolidations and excavations, which could be caused by COVID-19. Despite being treated for COVID-19, there was no clinical improvement. On the follow-up chest X-radiograohy, beside signs of COVID-19, there were also changes that could indicate Tuberculosis. Tuberculosis was detected in sputum, using PCR and Mycobacteria Growth Indicator Tube, and only after being treated for both diseases did his condition improve. Conclusion. There are a few reported cases of COVID-19 and Tuberculosis coinfections, and we believe that there are many more patients with this coinfection being unrecognized.

show abstract

“…The effect of SARS‐CoV2 induced pneumonia on the patients suffering from active and passive TB is unclear and need immediate investigations. The pandemic is already hampering the detection and treatment of TB [19,20] . The number of tuberculosis patients who are detected and treated within 3 months will drop by 25 % to 50 %.…”

Section: Introductionmentioning

confidence: 99%

Mycobacterial Membrane Protein Large 3 (MmpL3) Inhibitors: A Promising Approach to Combat Tuberculosis

Umare

Khedekar

Chikhale³

2021

ChemMedChem

View full text Add to dashboard Cite

Tuberculosis is a prominent aliment throughout the world and a leading cause of mortality among infectious diseases. Drug development for multi‐drug resistance and reducing the current therapy time is the top priority. Mycobacterial membrane protein large 3 (MmpL3) is a promising target with high potential, however, it has not been explored to its greatest potential. It is a membrane transporter that translocates trehalose‐monomycolate which is a precursor for the synthesis of mycolic acid that is essential for the synthesis of the bacterial cell wall and is pathogenic in nature. In this review, we have discussed the current development of MmpL3 inhibitors, different scaffolds, their derivatives, and their synthetic schemes and provide insight into the challenges in developing these inhibitors.

show abstract

COVID 19 and tuberculosis

Cited by 30 publications

References 4 publications

The possible impact of socioeconomic, income, and educational status on adverse effects of drug and their therapeutic episodes in patients targeted with a combination of tuberculosis interventions

The possible impact of socioeconomic, income, and educational status on adverse effects of drug and their therapeutic episodes in patients targeted with a combination of tuberculosis interventions

Unrecognized tuberculosis in a patient with COVID-19

Mycobacterial Membrane Protein Large 3 (MmpL3) Inhibitors: A Promising Approach to Combat Tuberculosis

Contact Info

Product

Resources

About